Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients

by AbilityPharma

10 years ago
ABTL0812, carboplatin, paclitaxel, cancer, lung, endometrial cancer

ABTL0812 is administered in combination with carboplatin and paclitaxel. Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona) lead...

Ability Pharmaceuticals enters into a licensing agreement with SciClone Pharmaceuticals for the novel anticancer agent ABTL0812 for the China market

by AbilityPharma

10 years ago
PI3K/Akt/mTOR, ABTL0812, lung cancer, endometrial cancer, SciClone Pharmaceuticals

Collaboration boosts development of a fully differentiated inhibitor of the PI3K/Akt/mTOR pathway. ABTL0812 is currently in Phase 2 clinical trials to treat lung and endometrial cancers.

Ability Pharmaceuticals announces positive Phase 1/1b study results of ABTL0812 in cancer patients with advanced solid tumors

by AbilityPharma

11 years ago
cancer, ABTL0812, drug development, advanced solid tumors

Study confirms that ABTL0812 is extremely well tolerated and shows promising signs of clinical antitumor activity. The results will be presented at AACR-NCI-EORTC International Conference on Molecular...

Ability Pharmaceuticals announces regulatory milestones for ABTL0812 in pediatric cancer neuroblastoma

by AbilityPharma

11 years ago
pediatric cancer, neuroblastoma, orphan-drug, ABTL0812, Food and Drug Administration

Ability Pharmaceuticals today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation (ODD) for ABTL0812, its PI3K/Akt/mTOR pathway inhibitor, for the ...